Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

364 enrolled

Triple Negative Breast Neoplasms

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

Triple Negative Breast Neoplasms

NCT06966700 2026-04-13

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Phase 2/3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07413939 2026-04-09

BREnnA

650 enrolled

HER2-positive Breast Cancer

NCT05064085 2026-04-06

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Phase 1 Completed

13 enrolled

Breast Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

BreastHead & NeckThoracic

1,000 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07112053 2026-04-06

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

40 enrolled

Anatomic Stage IV Breast Cancer AJCC v8

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast Neoplasms

NCT06312176 2026-04-02

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT02445391 2026-04-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

415 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07494448 2026-03-27

JAZMINE

24 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07486687 2026-03-20

PLANET

1,000 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07467330 2026-03-12

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

258 enrolled

Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

263 enrolled

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

100 enrolled

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

400 enrolled

Breast Neoplasms, Recurrence

NCT06435429 2026-02-10

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

550 enrolled

Metastatic HER2-positive Breast Cancer

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT06374459 2026-02-09

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

152 enrolled

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

524 enrolled

Phase 2/3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

350 enrolled

Triple Negative Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

297 enrolled

Breast Neoplasms

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

566 enrolled

HER2-low Breast Cancer

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

1,514 enrolled

Triple Negative Breast Neoplasms

NCT05693766 2026-01-20

INSIGHT

64 enrolled